Peer-reviewedCC BYAnnals of clinical and translational neurology
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
- 1Northwestern University
Related
- Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
- Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
- Comparative Short-Term Risk of Severe Gastrointestinal Events Associated with Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
BibTeX
@article{chang2026glucagonlike,
title = {{Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review}},
author = {Audrey Y. Chang and Farrah J. Mateen},
journal = {Annals of clinical and translational neurology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13655708},
note = {CC BY},
}
RIS
TY - JOUR
TI - Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
AU - Audrey Y. Chang
AU - Farrah J. Mateen
PY - 2026
DA - 2026/10/12
JO - Annals of clinical and translational neurology
UR - https://europepmc.org/article/PMC/PMC13655708
SN - 2328-9503
ER -